Drugs / glycerinated HDM allergen extract
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03763630 Comparator | Sep 2017 → Dec 2018 | asthma | University of Southampton | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glycerinated HDM allergen extract | “received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day.” NCT03763630 ↗ |
| Known as | ALK-AbellÓ | “received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day.” NCT03763630 ↗ |
| Modality | Other / unclassified | “house dust-mite immunotherapy” NCT03763630 ↗ |
| Route | Oral | “11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.” NCT03763630 ↗ |